Effects of Continuous Positive Airway Pressure (CPAP) in Patients With Resistant Hypertension and Obstructive Sleep Apnea (OSA)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Obstructive sleep apnea (OSA) is an important cause of refractory hypertension but the impact of treatment with continuous positive airway pressure (CPAP) is not completely understood. The aim of this project is to study the effects of CPAP on blood pressure control and its influences on cardiac remodeling and arterial stiffness in patients with refractory hypertension and moderate or severe OSA.
| Condition | Intervention | Phase |
|---|---|---|
|
Obstructive Sleep Apnea Refractory Hypertension |
Device: CPAP |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effects of Continuous Positive Airway Pressure in Patients With Resistant Hypertension and Obstructive Sleep Apnea |
- Ambulatory blood pressure monitoring [ Time Frame: Change from Baseline in Blood Pressure at 6 months ] [ Designated as safety issue: Yes ]
- Change from Baseline in Arterial stiffness at 6 months [ Time Frame: baseline and 6 months ] [ Designated as safety issue: Yes ]
- change from baseline in heart remodeling at 6 months [ Time Frame: baseline and 6 months ] [ Designated as safety issue: Yes ]
| Enrollment: | 40 |
| Study Start Date: | October 2008 |
| Study Completion Date: | March 2011 |
| Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| No Intervention: 1 | |
|
Active Comparator: 2
CPAP
|
Device: CPAP
Gold standard treatment for Obstructive sleep apnea
|
Detailed Description:
Study design Interventional, open-label, randomized.
Patients selection
Fifty refractory hypertensive patients with moderate-to-severe OSA, aged between 30 to 65 years old will be recruited from the outpatient clinics of the Heart Institute by the hospital staff.
Refractory hypertension will be defined as usually: blood pressure higher than or equal to 140x90 mmHg after a regimen of three drugs, including a diuretic for a minimum of 3 months. Initial evaluation will consist on ambulatory blood pressure measurement for 24 hours and a detailed clinical examination. Moderate to severe OSA will be defined as an apnea-hypopnea index > 15 evens per hour, after an overnight polysomnography.
Exclusion criteria include BMI >40 kg/m2; diabetes mellitus; aortic, heart and valve diseases; renal failure; other identifiable causes of hypertension, no adherence, use of cocaine, amphetamines, other illicit drugs, sympathomimetics (decongestants, anorectics), oral contraceptive hormones, nonsteroidal anti-inflammatory drugs.
Refractory hypertension Secondary causes of hypertension will be excluded using usual procedures from the Hypertension Unit.
Polysomnography All participants will be submitted to standard overnight polysomnography (EMBLA - Flagra hf. Medical Devices, Reykjavik, Iceland). The apnea-hypopnea index will be calculated as the total number of respiratory events (apneas plus hypopneas) per hour of sleep.
Apnea will be defined as an air flow cessation greater than 10 seconds and hypopnea as a reduction grater than 50% with oxygen saturation fall grater than 4% or arousal.
After recruitment, patients will be instructed about CPAP working by an experimented professional and another polysomnography will be done to adjust pressures. Hour counter will be used to check the adherence to CPAP.
Intervention Patients will be divided in two groups: medical treatment plus CPAP or medical treatment alone for 6 months without drug dose changing.
Twenty-four hour blood pressure monitoring Twenty-four hour blood pressure monitoring (system SpaceLabs 90207) will be used in all patients in the beginning and at the end of the study.
Arterial Stiffness Carotid-femoral arterial stiffness will be determined by Complior.
Echocardiography Echocardiography will be performed by using a commercially available machine.
Eligibility| Ages Eligible for Study: | 30 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Refractory hypertensive patients with moderate-to-severe OSA, aged between 30 to 65 years old.
Exclusion Criteria:
- Aortic, heart and valve diseases
- Renal failure
- Other identifiable causes of hypertension, no adherence, use of cocaine, amphetamines, other illicit drugs, sympathomimetics (decongestants, anorectics), oral contraceptive hormones, nonsteroidal anti-inflammatory drugs.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Geraldo Lorenzi-Filho, MD; PhD, University of Sao Paulo |
| ClinicalTrials.gov Identifier: | NCT00812695 History of Changes |
| Other Study ID Numbers: | RH-OSA |
| Study First Received: | December 19, 2008 |
| Last Updated: | November 21, 2011 |
| Health Authority: | Brazil: National Committee of Ethics in Research |
Keywords provided by University of Sao Paulo:
|
Obstructive sleep apnea Refractory hypertension Heart remodeling Arterial stiffness CPAP |
Additional relevant MeSH terms:
|
Apnea Hypertension Sleep Apnea Syndromes Sleep Apnea, Obstructive Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory |
Signs and Symptoms Vascular Diseases Cardiovascular Diseases Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013